Zhiru Yang
Novo Nordisk
4 Papers
Zhiru Yang is an academic researcher from Novo Nordisk. The author has contributed to research in topics: Emicizumab & Protein ligand. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand
Linda Yang,Chih-Chuan Chang,Zhe Sun,Dennis Madsen,Haisun Zhu,Søren Berg Padkjær,Xiaoai Wu,Tao Huang,Karin Hultman,Sarah J Paulsen,Jishu Wang,Anne Bugge,Jane Boesen Frantzen,Per Nørgaard,Jacob Jeppesen,Zhiru Yang,Anna Secher,Haibin Chen,Xun Li,Linu M. John,Bing Shan,Zhenhua He,Xiang Gao,Jing Su,Kristian Tage Hansen,Wei Yang,Sebastian Beck Jørgensen +26 more
TL;DR: It is shown that GDF15 binds specifically to GDNF family receptor α-like (GFRAL) with high affinity, and that GFRAL requires association with the coreceptor RET to elicit intracellular signaling in response to GDF 15 stimulation.
549
A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
Henrik Østergaard,Jacob Lund,Per Jr Greisen,Stine Kjellev,A. Henriksen,Nikolai Lorenzen,Eva Johansson,Gustav Røder,Morten Grønbech Rasch,Laust Bruun Johnsen,Thomas Egebjerg,Søren Lund,Henrik Rahbek-Nielsen,Prafull S. Gandhi,Kasper Lamberth,Mette Loftager,Lisbeth Moreau Andersen,Amalie Carnbring Bonde,Fabian Stavenuiter,Daniel Elenius Madsen,Xun Li,Thomas Lindebo Holm,Carsten Dan Ley,Peter Thygesen,Haisun Zhu,Rong Zhou,Karina Thorn,Zhiru Yang,Mette B. Hermit,Jais Rose Bjelke,Bjarne Gram Hansen,Ida Hilden +31 more
TL;DR: Mim8 as mentioned in this paper is an activated FVIII mimetic with a potent and efficacious hemostatic effect based on preclinical data, which is a bispecific antibody assembled with FIXa and FX on membranes, and supported activation with an apparent equilibrium dissociation constant of 16 nM.
49
Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo
Stine Kjellev,Henrik Østergaard,Per Jr Greisen,Mette B. Hermit,Karina Thorn,Bjarne Gram Hansen,Rong Zhou,Jais Rose Bjelke,Marianne Kjalke,Jacob Lund,Thomas L Holm,Carsten Dan Ley,Daniel Elenius,Peter Thygesen,Mette Loftager,Morten Grønbech Rasch,Nikolai Lorenzen,Prafull S. Gandhi,Kasper Lamberth,Thomas Egebjerg,Søren Lund,A. Henriksen,Henrik Rahbek-Nielsen,Zhiru Yang,Ida Hilden +24 more
TL;DR: Mim8 has a high potency allowing for administration of small volumes in a pen device, good PK parameters, minimal target binding in the blood, and good biophysical properties that support clinical development of Mim8 as a potentially improved next-generation FVIII-mimetic prophylactic treatment option for persons with hemophile A regardless of inhibitor status.
Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening.
Wei Yang,Søren Berg Padkjær,Jishu Wang,Zhe Sun,Bing Shan,Li Yang,Haibin Chen,Lishan Kang,Dennis Madsen,Xun Li,Chenxi Shen,Bingke Yu,Haisun Zhu,Tzu-Yuan Chao,Zhuoxiao Cao,Dapeng Li,Liu Wei,Yanping Du,Jinjing Xu,Dongxia Hao,Fengting Xu,Lujia Peng,Tengkun Li,Lin Wang,Lin Li,Haimei Xing,Di Liu,Zibing Liu,Zhishuang Guan,Wan Wang,Hong Cheng,Henrik Østergaard,Chih-Chuan Chang,Zhiru Yang,Esper Boel,Jing Su +35 more
TL;DR: The cell surface displayed library was screened against V-domain Ig suppressor of T-cell activation (VISTA), an important immune-checkpoint regulator and Immunoglobulin superfamily member 11 (IgSF11), a potential target for cancer immunotherapy, was identified as a new and previously undescribed binding partner for VISTA.